Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2013 Sep;94(3):407-11. doi: 10.1038/clpt.2013.126. Epub 2013 Jun 12.

A forensic analysis of drug targets from 2000 through 2012.

Author information

  • 1InnoThink Center for Research in Biomedical Innovation, Indianapolis, Indiana, USA. bhmunos@stanfordalumni.org

Abstract

Pharmaceutical innovation is often measured by counting the new drugs approved by regulators. It is a simple and useful metric, but it has shortcomings. One of them is that it says little about the drugs' innovativeness. Are they variations of older medicines or molecules targeting entirely novel modes of action? As prices escalate, and payers and patients demand value, we need a better picture. This article aims to provide it by analyzing the drugs approved by the US Food and Drug Administration between 2000 and 2012. It examines their modes of action, highlights key trends, and discusses their implications for our ability to generate innovation.

PMID:
23756372
DOI:
10.1038/clpt.2013.126
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center